Colorectal cancer diagnostic solutions
Colorectal cancer is a major health concern in the world today. The stages and subtypes of colorectal cancer vary significantly in prognosis and treatment options, demonstrating a need for tools that assist pathologists in detecting and subtyping colorectal malignancies.
Ventana offers a robust menu of tools to aid in colorectal cancer diagnosis. Our portfolio of assays, including IHC diagnostic assays, deliver the high sensitivity and specificity you need. Our antibodies are ready to use on the fully-automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions.
For example, The BRAF V600E (VE1) Mouse Monoclonal Primary Antibody is the first ready-to-use IVD immunohistochemistry (IHC) antibody that empowers you to evaluate the expression of BRAF V600E mutation with clinical confidence.
MLH-1 (M1) Mouse Monoclonal Primary Antibody is used to qualitatively identify human DNA mismatch repair (MMR) protein MLH1, expressed in the nucleus of normal proliferating cells. Loss of MLH1 is associated with colorectal and other cancers.
PMS2 (EPR3947) antibody is indicated as an aid in diagnostic determination of MSI-H tumors within the context of the patient’s clinical history and other diagnostic tests evaluated by a qualified pathologist or physician
MSH2 (G219-1129) This antibody is used as an aid in the identification of microsatellite instability within the context of an antibody panel, the patient’s clinical history, and other diagnostic tests evaluated by a qualified pathologist.
CONFIRM anti-MSH6 (44) Mouse Monoclonal Antibody is used to qualitatively identify human DNA mismatch repair (MMR) protein MSH6, expressed in the nucleus of normal proliferating cells. Loss of MSH6 is associated with colorectal and other cancers.
BRAF V600E (VE1) Mouse Monoclonal Primary Antibody may be used to aid in the identification of the mutant protein, BRAF V600E.
CDX-2 (EPR2764Y) is a caudal-related homeobox transcription factor whose expression in the adult is normally restricted to the intestinal epithelium. Loss of CDX-2 protein expression has been correlated with loss of differentiation in colorectal cancers. Anti-CDX-2 antibody has been useful in distinguishing gastrointestinal origin of metastatic adenocarcinomas and carcinoids.
Patient or Customer Success Stories
BRAF V600E IHC
Learn from Dr. Jayesh Desai, Royal Melbourne Hospital, on the importance of the BRAF V600E mutation and the value of BRAF V600E testing with immunohistochemistry.
Learn about the colorectal cancer disease state, including global incidence, tissue diagnostics and testing guidelines.